about
Side effects of a dopamine agonist therapy for Parkinson's disease: a mini-review of clinical pharmacologyTurning On Lights to Stop Neurodegeneration: The Potential of Near Infrared Light Therapy in Alzheimer's and Parkinson's DiseaseMedication nonadherence in Parkinson's diseaseTherapy for Parkinson's disease: what is in the pipeline?Novel (Hetero)arylalkenyl propargylamine compounds are protective in toxin-induced models of Parkinson's diseaseNear-infrared 808 nm light boosts complex IV-dependent respiration and rescues a Parkinson-related pink1 modeln-butylidenephthalide protects against dopaminergic neuron degeneration and α-synuclein accumulation in Caenorhabditis elegans models of Parkinson's diseaseParkinson's Disease and Its Management: Part 1: Disease Entity, Risk Factors, Pathophysiology, Clinical Presentation, and DiagnosisInitial medication in patients of newly diagnosed Parkinson's disease in TaiwanMRI-Guided Focused Ultrasound in Parkinson's Disease: A ReviewMore than just dancing: experiences of people with Parkinson's disease in a therapeutic dance program.Willingness to pay for a new drug delivery in Parkinson patientsDeep brain stimulation for movement disordersPerioperative Management of Neurological Conditions.Long-acting versus standard non-ergot dopamine agonists in Parkinson's disease: a meta-analysis of randomized controlled trials.Can the disease course in Parkinson's disease be slowed?Cognitive and Psychiatric Effects of STN versus GPi Deep Brain Stimulation in Parkinson's Disease: A Meta-Analysis of Randomized Controlled TrialsDelayed transplantation of precursor cell-derived astrocytes provides multiple benefits in a rat model of Parkinsons.The VPS35 gene and Parkinson's disease.Is there a need to redefine Parkinson's disease?Animal models of Parkinson's disease: a gateway to therapeutics?Astrocytic modulation of blood brain barrier: perspectives on Parkinson's disease.Decreased long-chain acylcarnitines from insufficient β-oxidation as potential early diagnostic markers for Parkinson's disease.Novel Focused Ultrasound Gene Therapy Approach Noninvasively Restores Dopaminergic Neuron Function in a Rat Parkinson's Disease Model.New and emerging medical therapies in Parkinson's disease.Drug-Induced Dyskinesia, Part 1: Treatment of Levodopa-Induced Dyskinesia.Systemic human CD34(+) cells populate the brain and activate host mechanisms to counteract nigrostriatal degeneration.The c-Abl inhibitor, nilotinib, protects dopaminergic neurons in a preclinical animal model of Parkinson's disease.Mimicking Parkinson's Disease in a Dish: Merits and Pitfalls of the Most Commonly used Dopaminergic In Vitro Models.Movement disorders and neuromodulation.Does supplementation with carnosine improve cardiometabolic health and cognitive function in patients with pre-diabetes and type 2 diabetes? study protocol for a randomised, double-blind, placebo-controlled trial.Irisflorentin improves α-synuclein accumulation and attenuates 6-OHDA-induced dopaminergic neuron degeneration, implication for Parkinson's disease therapy.Effect of 24-h continuous rotigotine treatment on stationary and non-stationary locomotion in de novo patients with Parkinson disease in an open-label uncontrolled study.Accumulation of 123I-Ioflupane Is a Useful Marker of the Efficacy of Selegiline Monotherapy in Drug-Naïve Parkinson's Disease.Proceedings: cell therapies for Parkinson's disease from discovery to clinic.Factors associated with motor complications in Parkinson's disease.Part 2: Introduction to the Pharmacotherapy of Parkinson's Disease, With a Focus on the Use of Dopaminergic Agents.The pharmacokinetic evaluation of selegiline ODT for the treatment of Parkinson's disease.Subnanomolar indazole-5-carboxamide inhibitors of monoamine oxidase B (MAO-B) continued: indications of iron binding, experimental evidence for optimised solubility and brain penetration.Dopamine D2-like receptor activation wipes out preferential consolidation of high over low reward memories during human sleep.
P2860
Q26738349-58A89C83-70C0-4E13-8A1C-51939D9F0BE2Q26770462-753E83F6-0FE7-4968-9E99-1C7E0DDF515AQ26823300-98506F4C-5288-4E1A-B379-600A3248B79FQ26991826-D7B03923-F15B-4493-9C9F-FB034C9C4144Q27301283-E59BF1EB-AF27-4D16-8E1E-33F824584A09Q27303071-737AEB83-4715-4124-AC0D-E6F254693D47Q27334018-C9F6A20A-0241-4642-B751-4FD078513E85Q28384572-03E7D34B-4C0D-453A-B4F0-EB97737136A2Q28542989-BC23EAB3-C3EF-4FAF-979F-D8B0F29FB1A8Q30357442-2A62B6DB-01F3-440D-8B8D-DD923738331BQ30388429-538992CB-FDD9-4194-A62B-1CFFE83E8122Q30428083-9C8D8874-BD28-4FE6-BE6D-4DE5577AC45FQ30585845-01EB6293-B884-4DEB-9C90-F09F07275AA2Q33797928-03C56AEA-4567-4ECE-8435-5C6C69E79622Q35109436-1200CEDA-F374-4794-92B7-54DBDBA2215EQ35865171-0C00FCF5-1D5A-4C10-8AD2-B9FBC6B2C20BQ36036036-ED7FAF09-DC8B-4F23-8281-D97BCE7A631EQ37710820-FC5144FC-CB2E-4721-A161-73FE2D938E6DQ38093808-CC5E8B8E-A6DC-4B2C-9372-1A43DCF3A039Q38110209-BA51ABAB-AE1A-4446-893C-67AA3C17B644Q38155480-54B0892D-9FB0-42B4-9D80-EC05AD22DE02Q38241183-2060CB41-6AC2-41DD-B454-448F54BB0EEEQ38639708-45F71FC0-A127-4221-B285-26B026155A3DQ38703346-974C1B21-3843-4FBC-858D-28AD4D0E1EF7Q38718194-296522DC-88FF-4DA0-B922-CEA638B77CF9Q38811387-12330F2D-DF72-4FED-BFDF-7EDEC6A69825Q38846988-B8CEE5EE-01BF-4F84-95E2-0C84B37038BAQ39136811-36CE5C64-C187-46D5-B1CD-3F29A735B057Q39443289-0ADFBE93-F777-49B2-9EC8-5AA72F30F398Q39539487-ECBB7DC7-EEFD-4DCE-9F2B-971738E79816Q40060825-51E57139-B81A-478D-8EA1-C6437F959B9CQ41369321-2FFC678F-DAE4-4BED-98EB-1CF75D988998Q41455787-863FE0A6-0A39-4037-A06C-352D814A1430Q42369753-555078B3-7EEA-472E-9915-F1A57E0F91A3Q42545361-DC51933C-D61E-450F-9CCD-D16A8D3621FEQ42655862-2369FCE8-86C9-443F-A7CF-D4A6AD2FECD7Q43248920-40F1B347-AD3A-454E-B3A6-B3F7537315E2Q43637473-FAB791CB-BCE9-4BE6-9E49-9C02318E4C4DQ47964614-B1ECFC8D-D81C-4816-9FE8-866789E86EC6Q48117172-ECB1316E-A689-41F9-8022-5CC571E78C35
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Therapies in Parkinson's disease.
@en
type
label
Therapies in Parkinson's disease.
@en
prefLabel
Therapies in Parkinson's disease.
@en
P1476
Therapies in Parkinson's disease.
@en
P304
P356
10.1097/WCO.0B013E3283542FC2
P577
2012-08-01T00:00:00Z